Granulocyte colony-stimulating factor-mediated neuroprotective therapy for acute complete spinal cord injury patients

Granulocyte colony-stimulating factor-mediated neuroprotective therapy for acute complete spinal cord injury patients - Granulocyte colony-stimulating factor-mediated neuroprotective therapy for acute complete spinal cord injury patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013955

Enrollment

Registered

2014-05-14

Start date

2014-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute complete spinal cord injury

Interventions

G-CSF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: acute spinal cord injury with complete paralysis patients who agree with the participation to the present trial

Exclusion criteria

Exclusion criteria: 1. Allergy for G-CSF 2. Hematologic malignancy 3. Past history of any kind of malignancy within 5 years 4. Severe co-morbidity 5. Thorombosis 6. Splenomegaly 7. Consciousness disorder 8. Pregnancy 9. Neurological disorder which can affect neurological evaluation in the present trial

Design outcomes

Primary

Measure	Time frame
ASIA motor score alteration 3 months after G-CSF aadministration	—

Secondary

Measure	Time frame
Change in AIS adverse events	—

Countries

Japan

Contacts

Public ContactYukiko Matsumoto

Chiba University Graduate School of Medicine Department of Orthopedic Surgery

chibaseikei8f@yahoo.co.jp043-226-2961

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026